Background: Current randomized trials have demonstrated the effects of short-term rosuvastatin therapy in preventing contrast-induced acute kidney injury (CIAKI).However, the consistency of these effects on patients administered different volumes of contrast media is unknown.Methods: In the TRACK-D trial, 2998 patients with type 2 diabetes and concomitant chronic kidney disease (CKD) who underwent coronary/peripheral arterial angiography with or without percutaneous intervention were randomized to short-term (2 days before and 3 days after procedure) rosuvastatin therapy or standard-of-care.This prespecified analysis compared the effects of rosuvastatin versus standard therapy in patients exposed to (moderate contrast volume [MCV], 200-300 ml, n =712) or (high contrast volume [HCV], ≥300 ml, n =220).The primary outcome was the incidence of CIAKI.The secondary outcome was a composite of death, dialysis/hemofiltration or worsened heart failure at 30 days.Results: Rosuvastatin treatment was associated with a significant reduction in CIAKI compared with the controls (2.1% vs.4.4%,P =0.050) in the overall cohort and in patients with MCV (1.7% vs.4.5%, P =0.029), whereas no benefit was observed in patients with HCV (3.4% vs.3.9%, P =0.834).The incidence of secondary outcomes was significantly lower in the rosuvastatin group compared with control group (2.7% vs.5.3%, P =0.049) in the overall cohort, but it was similar between the patients with MCV (2.0% vs.4.2%, P =0.081) or HCV (5.1% vs.8.8%, P =0.273).Conclusions: Periprocedural short-term rosuvastatin treatment is effective in reducing CIAKI and adverse clinical events for patients with diabetes and CKD after their exposure to a moderate volume of contrast medium.